Abstract Search

ey0018.9-4 | Thyroid disorders in inflammatory bowel diseases | ESPEYB18

9.4. Infliximab therapy could decrease the risk of the development of thyroid disorders in pediatric patients with Crohn's Disease

A Furtak , AM Wedrychowicz , M Sladek , A Wedrychowicz , K Fyderek , J Starzyk

Front Endocrinol (Lausanne). 2020; 11: 558897. https://pubmed.ncbi.nlm.nih.gov/33042019/This patient cohort study evaluated the prevalence of autoimmune thyroid diseases (AITDs), defined as decreased thyroid echogenicity in 61 children with Crohns disease, 25 infliximab (IFX)-naïve (control group) and 36 IFX-treated patients (mean duration of IFX therapy 13.9±16.6 months). T...

0 shares

ey0020.7-12 | Adrenal Function and Cancer Treatment | ESPEYB20

7.12. The assessment of the hypothalamic-pituitary-adrenal axis after oncological treatment in pediatric patients with acute lymphoblastic leukemia

B Hull , A Wędrychowicz , M Ossowska , A Furtak , J Badacz , S Skoczeń , JB Starzyk

Brief summary: Chemotherapy, radiotherapy and corticosteroids used to treat acute lymphoblastic leukemia (ALL) can have endocrine side-effects, such as adrenal insufficiency (AI). This cross-sectional single-centre study aimed to assess AI frequency after completion of ALL therapy, by comparison to healthy controls matched for age and sex, and to identify biomarkers of adrenal function and reserve.Study patients were at least 16 months post-completion of...

0 shares

ESPE Yearbook of Paediatric Endocrinology

9.4. Infliximab therapy could decrease the risk of the development of thyroid disorders in pediatric patients with Crohn's Disease

7.12. The assessment of the hypothalamic-pituitary-adrenal axis after oncological treatment in pediatric patients with acute lymphoblastic leukemia

BiosciAbstracts